Hansa Biopharma — Marts 2025
-
Presentations:
https://www.hansabiopharma.com/files/Presentations/2025/20250305-HNSA_TDCowen_STulstrup.pdf
(5 March 2025)
-
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
Lund, Sweden, 11 March 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), announced
News Powered by Cision (news.cision.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind